SPS
ESPR

Susquehanna Portfolio Strategies’s Esperion Therapeutics ESPR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-92,300
Closed -$247K – 591
2024
Q1 		$247K Sell
92,300
-23,946
-21% -$58.2K 0.01% 703
2023
Q4 		$348K Buy
+116,246
New +$151K 0.01% 833

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Portfolio Strategies's ESPR Position: Q2 2024 in Review

Susquehanna Portfolio Strategies sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 92,300 shares — an estimated $247K sold.

Susquehanna Portfolio Strategies first reported a position in ESPR in Q4 2023 and held it in 2 quarters. The position peaked at $348K in Q4 2023. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Susquehanna Portfolio Strategies reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 92,300 Esperion Therapeutics shares in Q2 2024, an estimated $247K.
  • Susquehanna Portfolio Strategies first reported a position in Esperion Therapeutics in Q4 2023 and held it in 2 quarters.
  • Susquehanna Portfolio Strategies's Esperion Therapeutics position peaked at $348K in Q4 2023.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2024, filed 15 Aug 2024.